China Population Policies Impact on Healthcare Companies Series – Part 2
856 Views03 Oct 2023 09:19
SUMMARY
- Several provinces have successively introduced policies to encourage childbirth. Increasing medical insurance reimbursement and special additional deduction standards for personal income tax would be the common direction.
- This year is mainly a period of intensive introduction of relevant fertility support policies, so the impact on company’s performance is limited.The focus would be on next year's financial results.
- We analyzed the performance of Livzon Pharmaceutical Group In (000513 CH),BGI Genomics (300676 CH) and Jinxin Fertility Group (1951 HK) based on their 23H1 reports, and adjusted our forecast accordingly.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Population Policies Impact on Healthcare Companies Series – Part 419 Apr 2024
- China Population Policies Impact on Healthcare Companies Series - Part 305 Jan 2024
- China Healthcare Weekly (Sep.29) - Be Rational About Biotech Investment, R&D Team Layoffs, Huadong01 Oct 2023
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
- Jinxin Fertility Co Ltd (1951.HK) - Hard to Achieve Performance Reversal in 202329 Dec 2022
x